S100A9 and neoplasm: It has been reported that in the microenvironment of cancer, S100A9 binds to RAGE on myeloid-derived suppressor cells (MDSCs) and promotes MDSC migration to the tumor site and represses host-mediated antitumor immune response against cancer cells, thereby facilitating carcinogenesis and tumor progression40,41.